{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:58:27Z","timestamp":1790913507102,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":212,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101351","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:59:07Z","timestamp":1786049947000},"page":"101351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC"],"prefix":"10.1016","volume":"48","author":[{"given":"Siobhan","family":"Halloran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman R.","family":"Punekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Guinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ondovik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Hamer-Maansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Cornfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Ayoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela C.","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-3755","authenticated-orcid":false,"given":"Kim","family":"Saverno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101351_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101351_bib0002","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2026.101351_bib0003","series-title":"Cancer Facts & Figures 2025","year":"2025"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101351_bib0004","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013Small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMa Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101351_bib0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101351_bib0006","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non\u2013Small cell lung cancer","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMa"},{"issue":"22","key":"10.1016\/j.ctarc.2026.101351_bib0008","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101351_bib0010","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.jcpo.2022.100346","article-title":"Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: a comparison of the regulatory approvals in Europe and the United States","volume":"33","author":"Zaim","year":"2022","journal-title":"J. Cancer Policy."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101351_bib0011","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101351_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.10.660","article-title":"627MO POD1UM-304: phase III study of retifanlimab plus platinum-based chemotherapy (Chemo) as first-line (1L) therapy for nonsquamous or squamous metastatic non\u2013small cell lung cancer (mNSCLC)","volume":"35","author":"Lu","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101351_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.01.1182","article-title":"P79.03 A phase 3 study of the PD-1 inhibitor retifanlimab (INCMGA00012) plus platinum-based chemotherapy in 1L mNSCLC: POD1UM-304","volume":"16","author":"Lu","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101351_bib0014","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1186\/s12885-025-14712-w","article-title":"The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis","volume":"25","author":"Zhao","year":"2025","journal-title":"BMC. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101351_bib0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00432-020-03414-4","article-title":"Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study","volume":"147","author":"Nadler","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101351_bib0016","article-title":"Treatment patterns for advanced non-small cell lung cancer in the US: a systematic review of observational studies","volume":"33","author":"Lee","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101351_bib0017","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101351_bib0018","article-title":"Therapy for stage IV non\u2013small cell lung cancer without driver alterations: ASCO Living Guideline, Version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101351_bib0019","article-title":"The state of cancer care in America, 2017: a report by the American Society of Clinical Oncology","volume":"13","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ctarc.2026.101351_bib0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.critrevonc.2018.07.002","article-title":"Concern over cost of and access to cancer treatments: a meta-narrative review of nivolumab and pembrolizumab studies","volume":"129","author":"da Veiga","year":"2018","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101351_bib0021","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e20565","article-title":"NSCLC in the immunotherapy era: trends in survival and disparities across demographic and socioeconomic groups","volume":"43","author":"Peshin","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101351_bib0022","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/jnci\/djae118","article-title":"Racial and socioeconomic disparities in survival among patients with metastatic non\u2013small cell lung cancer","volume":"116","author":"Uprety","year":"2024","journal-title":"JNCI: J. Nat. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101351_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/OA.24.00008","article-title":"Disparities in utilization of immune checkpoint inhibitor therapy among older patients with advanced non\u2013Small cell lung cancer: a SEER-medicare analysis","volume":"1","author":"Yang","year":"2024","journal-title":"JCO Oncol. Adv."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101351_bib0024","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jnci\/djae225","article-title":"Racial and socioeconomic disparities in non\u2013small cell lung cancer molecular diagnostics uptake","volume":"117","author":"Tuminello","year":"2025","journal-title":"JNCI: J. Nat. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101351_bib0025","doi-asserted-by":"crossref","first-page":"8190","DOI":"10.1038\/s41598-023-35216-2","article-title":"Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database","volume":"13","author":"Gupta","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101351_bib0026","article-title":"Database characterization Guide","year":"2025","journal-title":"Flatiron.com"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101351_bib0027","article-title":"Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022","volume":"7","author":"Guadamuz","year":"2023","journal-title":"JNCI. Cancer Spectr."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101351_bib0028","first-page":"S29","article-title":"Effect modification of the association between race and stage at colorectal cancer diagnosis by socioeconomic status","volume":"25","author":"McGrew","year":"2019","journal-title":"J. Public Health Manag. Pr."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101351_bib0029","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101351_bib0030","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2217\/imt-2021-0145","article-title":"Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101351_bib0031","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s12885-024-12126-8","article-title":"Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer","volume":"24","author":"Divan","year":"2024","journal-title":"BMC. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101351_bib0032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/curroncol32030151","article-title":"Real-world treatment patterns, healthcare resource utilization, and healthcare costs in the first-line treatment of metastatic non-small cell lung cancer in the US","volume":"32","author":"Chopra","year":"2025","journal-title":"Curr. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101351_bib0033","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1007\/s12325-022-02260-9","article-title":"Characterizing the shifting real-world treatment landscape by PD-L1 testing status and expression level in advanced non-small cell lung cancer","volume":"39","author":"Ge","year":"2022","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101351_bib0034","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/jnci\/djab116","article-title":"Smoking history as a potential predictor of immune checkpoint inhibitor efficacy in metastatic non-small cell lung cancer","volume":"113","author":"Wang","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101351_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100990","article-title":"The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: a systematic review and meta-analysis","volume":"38","author":"Dai","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctarc.2026.101351_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1422160","article-title":"Effect of smoking status on immunotherapy for lung cancer: a systematic review and meta-analysis","volume":"14","author":"Luo","year":"2024","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101351_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.12534","article-title":"Association of sex, age, and Eastern Cooperative Oncology Group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis","volume":"3","author":"Yang","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ctarc.2026.101351_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108661","article-title":"Disparities in adherence to guideline-concordant care and receipt of immunotherapy for non-small cell lung cancer in the United States","volume":"206","author":"Nykaza","year":"2025","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101351_bib0039","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/jnci\/djad132","article-title":"Unequal racial distribution of immunotherapy for late-stage non\u2013small cell lung cancer","volume":"115","author":"Chang","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101351_bib0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101351_bib0041","first-page":"166","article-title":"Minimizing the burden of cancer in the United States: goals for a high-performing health care system","volume":"69","author":"Yabroff","year":"2019","journal-title":"CA Cancer J. Clin."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:52:28Z","timestamp":1790913148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":39,"alternative-id":["S2468294226002625"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101351","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the clinical trial: Real-world treatment patterns and drivers of PD-(L)1 therapy use in first-line metastatic NSCLC","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Incyte Corporation. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101351"}}